拱东医疗：关于"提质增效重回报"行动方案的公告 截至2025年12月26日收盘，拱东医疗（605369）报收于18.81元，较上周的18.54元上涨1.46%。本周， 拱东医疗12月25日盘中最高价报19.4元。12月23日盘中最低价报18.06元。拱东医疗当前最新总市值 41.47亿元，在医疗器械板块市值排名84/127，在两市A股市值排名3839/5178。 本周关注点 公司公告汇总：拱东医疗发布"提质增效重回报"行动方案，涵盖研发、生产、市场及分红等举 措。 公司公告汇总 浙江拱东医疗器械股份有限公司于2025年12月22日审议通过《"提质增效重回报"行动方案》，旨在通过 聚焦主业升级、规范治理、优化投资者关系、强化回报机制等举措，提升公司经营质量与投资价值。方 案包括加大研发投入、推进智能化生产、拓展国内外市场、完善公司治理、加强信息披露、实施稳定分 红等内容，切实保护投资者权益。该方案不构成对投资者的实质承诺，存在不确定性。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：605369 证券简称：拱东医疗 公告编号：2025-037 浙江拱东医疗器械股份有限公司 关于"提质增效重回报"行动方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 为深入贯彻落实国务院《关于进一步提高上市公司质量的意见》要求，积极响应上海证券交易所《关于 开展沪市公司"提质增效重回报"专项行动的倡议》，浙江拱东医疗器械股份有限公司（以下简称"公 司"）立足医疗器械行业发展趋势，结合自身核心业务优势、经营实际情况及长远发展战略，基于对公 司未来持续稳定发展的信心和对公司价值的认可，制定本《"提质增效重回报"行动方案》（以下简 称"行动方案"）。旨在通过聚焦主业升级、规范治理运作、优化投资者关系、强化回报机制等举措，持 续提升公司核心竞争力与经营质量，推动公司高质量发展与投资价值提升，切实保护投资者尤其是中小 投资者的合法权益。本次行动方案已于2025年12月22日经公司第三届董事会第十九次会议审议通过，具 体内容如下： 一、聚焦主营业务，提升经营质量 公司 ...

公司公告汇总 拱东医疗：关于"提质增效重回报"行动方案的公告 截至2025年12月22日收盘，拱东医疗(605369)报收于18.19元，下跌1.89%，换手率0.57%，成交量1.26万 手，成交额2310.62万元。 当日关注点 交易信息汇总资金流向 12月22日主力资金净流出340.95万元，占总成交额14.76%；游资资金净流入159.2万元，占总成交额 6.89%；散户资金净流入181.75万元，占总成交额7.87%。 浙江拱东医疗器械股份有限公司于2025年12月22日审议通过《"提质增效重回报"行动方案》，旨在通过 聚焦主业升级、规范治理、优化投资者关系、强化回报机制等举措，提升公司经营质量与投资价值。方 案涵盖加大研发投入、推进智能化生产、拓展国内外市场、完善公司治理、加强信息披露、实施稳定分 红等内容，切实保护投资者权益。该方案不构成对投资者的实质承诺，存在不确定性。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 来自交易信息汇总：12月22日主力资金净流出340.95万元，占总成交额14.76%。 来自公司公告 ...

证券代码：605369 证券简称：拱东医疗 公告编号：2025-037 浙江拱东医疗器械股份有限公司 关于"提质增效重回报"行动方案的公告 | 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 | | --- | | 漏，并对其内容的真实性、准确性和完整性承担法律责任。 | 为深入贯彻落实国务院《关于进一步提高上市公司质量的意见》要求，积极响 应上海证券交易所《关于开展沪市公司"提质增效重回报"专项行动的倡议》，浙 江拱东医疗器械股份有限公司（以下简称"公司"）立足医疗器械行业发展趋势， 结合自身核心业务优势、经营实际情况及长远发展战略，基于对公司未来持续稳定 发展的信心和对公司价值的认可，制定本《"提质增效重回报"行动方案》（以下 简称"行动方案"）。旨在通过聚焦主业升级、规范治理运作、优化投资者关系、 强化回报机制等举措，持续提升公司核心竞争力与经营质量，推动公司高质量发展 与投资价值提升，切实保护投资者尤其是中小投资者的合法权益。本次行动方案已 于2025年12月22日经公司第三届董事会第十九次会议审议通过，具体内容如下： 一、聚焦主营业务，提升经营质量 公司是国内医疗器械行 ...

Core Points - The major shareholders of Gongdong Medical have reduced their holdings, with the controlling shareholder Shi Huiyong decreasing his stake from 50.27% to 48.27% and Jinchi Investment reducing from 6.47% to 5.47% [1] - The total amount of shares reduced by Shi Huiyong is 4,402,400 shares, while Jinchi Investment has reduced 2,204,840 shares, resulting in a combined reduction of approximately 11.92 million yuan [1] - Shi Huiyong and Jinchi Investment have cumulatively cashed out approximately 12.39 million yuan from their holdings [3] Shareholder Details - Shi Huiyong and Shi Yibei are father and daughter, with Shi Huiyong being the general partner and executive partner of Jinchi Investment [2] - Together, Shi Huiyong, Shi Yibei, and Jinchi Investment hold a total of 141,558,049 shares, representing 64.21% of the company's total equity [2] - Jinchi Investment is an employee stock ownership platform, and Shi Huiyong did not participate in the recent reduction of shares by Jinchi Investment [2] Historical Context - Shi Huiyong initially held 42 million shares, which was 52.50% of the total equity, and has cumulatively reduced 3,151,400 shares since July 26, 2024, cashing out approximately 8.04 million yuan [2] - Jinchi Investment initially held 6 million shares, or 7.50% of the total equity, and has cumulatively reduced 1,575,700 shares since March 11, 2025, cashing out approximately 4.36 million yuan [2]

Core Viewpoint - The announcement details the share reduction by major shareholders of Zhejiang Gongdong Medical Instrument Co., Ltd., including the results of the reduction and changes in equity ownership [1][10]. Group 1: Shareholder and Ownership Information - The controlling shareholder, Shi Huiyong, held 110,836,040 shares, representing 50.27% of the total share capital before the reduction. Taizhou Jinch Investment Management Partnership held 14,258,009 shares, accounting for 6.47% [2]. - After the reduction, Shi Huiyong holds 106,433,640 shares (48.27%), while Jinch Investment holds 12,053,169 shares (5.47%) [3]. Group 2: Reduction Plan Implementation Results - The reduction plan was announced on September 5, 2025, allowing Shi Huiyong to reduce up to 4,409,858 shares and Jinch Investment to reduce up to 2,204,929 shares within the specified period from September 26 to December 24, 2025 [3][8]. - By December 16, 2025, Shi Huiyong had reduced 4,402,400 shares, and Jinch Investment had reduced 2,204,840 shares, completing the reduction plan [3][11]. Group 3: Equity Change Details - The equity change occurred between October 31 and December 16, 2025, with Shi Huiyong and Jinch Investment's combined shareholding decreasing from 141,017,809 shares (63.96%) to 134,950,809 shares (61.21%) [9]. - The reduction did not trigger a mandatory tender offer and will not significantly impact the company's governance structure or ongoing operations [10].

Group 1 - The core point of the article is that Gongdong Medical conducted a block trade on December 16, with a total transaction volume of 4.4024 million shares and a transaction amount of 76.2056 million yuan, at an average price of 17.31 yuan, reflecting a discount of 5.46% compared to the closing price of the day [1] Group 2 - The block trade details include six transactions, with the largest single transaction being 1 million shares at a price of 17.31 yuan, executed by institutional buyers through Zheshang Securities [1] - The total transaction volume and amount indicate significant trading activity, suggesting potential interest from institutional investors in Gongdong Medical [1]

证券代码：605369 证券简称：拱东医疗 公告编号：2025-036 浙江拱东医疗器械股份有限公司 股东减持股份结果暨权益变动触及 1%刻度公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 大股东及董监高持股的基本情况 本次减持计划实施前，公司控股股东、实际控制人施慧勇持有公司股份 110,836,040 股，占公司总股本的 50.27%。台州金驰投资管理合伙企业（有限合 伙）（以下简称"金驰投资"）持有浙江拱东医疗器械股份有限公司（以下简称"公 司"、"拱东医疗"）股份 14,258,009 股，占公司总股本的 6.47%。 减持计划的实施结果情况 2025年9月5日，公司披露了《股东减持股份计划公告》（公告编号：2025-029）， 自公告披露之日起 15 个交易日后的 3 个月内（即减持区间为：2025 年 9 月 26 日至 2025 年 12 月 24 日），公司控股股东、实际控制人施慧勇拟通过大宗交易 方式合计减持数量不超过 4,409,858 股，且在任意连续 90 日内，减持股份 ...

Core Viewpoint - Gongdong Medical (605369.SH) announced the completion of share reduction plans by key stakeholders, indicating potential changes in ownership structure and investor sentiment [1] Share Reduction Details - Mr. Shi Huiyong has reduced his holdings by 4.4024 million shares through block trading, while Jinch Investment has reduced its holdings by 2.2048 million shares through centralized bidding [1] - After the completion of the reduction plan, Mr. Shi holds 106 million shares, representing 48.27% of the company's total share capital, while Jinch Investment holds 12.0532 million shares, accounting for 5.47% of the total share capital [1]

Core Viewpoint - Gongdong Medical (605369.SH) announced the completion of share reduction plans by key shareholders, indicating potential changes in ownership structure and investor sentiment [1] Share Reduction Details - Mr. Shi Huiyong has reduced his holdings by 4.4024 million shares through block trading, while Jinch Investment has reduced its holdings by 2.2048 million shares through centralized bidding [1] - After the completion of the reduction plan, Mr. Shi holds 106 million shares, accounting for 48.27% of the company's total share capital, while Jinch Investment holds 12.0532 million shares, representing 5.47% of the total share capital [1]